Juno Therapeutics, Inc. (NASDAQ:JUNO) was the recipient of a large decrease in short interest during the month of September. As of September 29th, there was short interest totalling 9,481,474 shares, a decrease of 29.9% from the September 15th total of 13,519,026 shares. Based on an average daily trading volume, of 2,962,349 shares, the short-interest ratio is presently 3.2 days. Approximately 11.2% of the shares of the company are short sold.

Shares of Juno Therapeutics (JUNO) opened at 43.08 on Friday. The stock’s market cap is $4.52 billion. Juno Therapeutics has a 12-month low of $17.52 and a 12-month high of $47.03. The firm has a 50 day moving average price of $42.44 and a 200 day moving average price of $30.05.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The business had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $15.59 million. During the same quarter in the previous year, the firm earned ($0.64) earnings per share. Juno Therapeutics’s revenue was down 22.8% on a year-over-year basis. On average, equities analysts expect that Juno Therapeutics will post ($3.08) EPS for the current year.

In other news, insider Sunil Agarwal sold 7,285 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $44.76, for a total transaction of $326,076.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Richard Klausner sold 12,000 shares of the company’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $30.34, for a total value of $364,080.00. Following the transaction, the director now directly owns 788,985 shares in the company, valued at approximately $23,937,804.90. The disclosure for this sale can be found here. Insiders have sold a total of 85,004 shares of company stock worth $3,551,561 in the last ninety days. Insiders own 15.26% of the company’s stock.

Several institutional investors have recently made changes to their positions in JUNO. The Manufacturers Life Insurance Company lifted its position in shares of Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 228 shares in the last quarter. Pacad Investment Ltd. purchased a new stake in shares of Juno Therapeutics in the second quarter worth about $105,000. QS Investors LLC purchased a new stake in shares of Juno Therapeutics in the second quarter worth about $135,000. Great West Life Assurance Co. Can lifted its position in shares of Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 3,800 shares in the last quarter. Finally, Macquarie Group Ltd. purchased a new stake in shares of Juno Therapeutics in the second quarter worth about $248,000. Institutional investors and hedge funds own 67.38% of the company’s stock.

A number of brokerages recently issued reports on JUNO. Maxim Group reissued a “buy” rating and set a $56.00 price objective (up previously from $34.00) on shares of Juno Therapeutics in a report on Monday. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $44.00 price objective on shares of Juno Therapeutics in a report on Friday, October 6th. Morgan Stanley reissued an “equal weight” rating and set a $43.00 price objective (up previously from $27.00) on shares of Juno Therapeutics in a report on Friday, October 6th. Barclays PLC began coverage on Juno Therapeutics in a report on Wednesday, September 6th. They set an “overweight” rating and a $55.00 price objective on the stock. Finally, Wells Fargo & Company reissued an “outperform” rating and set a $54.00 price objective (up previously from $35.00) on shares of Juno Therapeutics in a report on Tuesday, September 5th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $37.83.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/13/juno-therapeutics-inc-juno-short-interest-update.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.